DRKS00033130
Recruiting
Not Applicable
Predicting the response to therapy of inflammatory bowel disease with infrared spectroscopy - PROPHECY
niversitätsklinikum Erlangen0 sites1,500 target enrollmentDecember 4, 2023
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- K51
- Sponsor
- niversitätsklinikum Erlangen
- Enrollment
- 1500
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •established diagnosis of ulcerative colitis or Crohn's disease
- •\- diagnostic ileocolonoscopy with biopsies and subsequent initiation of a novel anti\-inflammatory therapy
Exclusion Criteria
- •\- drugs, concomitant diseases or conditions that preclude the assessment of clinical response/remission
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Not Applicable
Prediction of the effect of treatments for inflammatory bowel disease patients by using colon ultra sonography imagingInflammatory bowel disease(IBD)JPRN-UMIN000002250Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine260
Recruiting
Not Applicable
Predicting response to biologics in inflammatory bowel diseaseInflammatory bowel diseaseOral and Gastrointestinal - Inflammatory bowel diseaseACTRN12613001292763niversity of Otago Christchurch160
Recruiting
Not Applicable
Prediction of therapy response and treatment outcomes in early course of schizophrenia.Subproject D1_AP2 of the research network ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments)DSM IV-TR:295.10-30, 295.90: Schizophrenia High Risc State of transmission to psychosisDRKS00010936Klinik und Poliklinik für Psychiatrie und Psychotherapie,LVR-Klinikum Düsseldorf / Kliniken der Heinrich Heine Universität Düsseldorf600
Completed
Not Applicable
Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).JPRN-UMIN000020134Jichi Medical University56
Completed
Not Applicable
Biomonitoring of inflammation, therapy response and regeneration in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis during therapy with Certolizumab PegolM06.99M07.00M45.00DRKS00012509Charité Campus Charité Mitte137